AdvaMed Presses for Predictable Trade and Regulatory Rules as Medtech Faces Policy Crosscurrents
Tariffs, FDA user-fee renewal, payment and coverage transparency, and cybersecurity are now the central policy concerns for AdvaMed, the trade group representing medical technology manufacturers, diagnostics companies, and digital health innovators. Scott Whitaker, the organization’s president and CEO, laid out the agenda at the AdvaMed MedTech Conference in Boston on Monday, placing a premium on predictability in a sector that depends on long development timelines, global supply chains, and complex reimbursement pathways.
His comments tracked the practical pressures facing device companies at every stage of the product lifecycle. A tariff regime that changes from one week to the next can alter sourcing decisions, factory planning, and pricing models before a product ever reaches a hospital. A reimbursement pathway that lacks clarity can stall adoption even after a product wins regulatory clearance. And as connected devices move deeper into clinical workflows, the security of patient data has become a core operational issue rather than a back-office IT concern.
Tariffs Are a Cost Problem, but Predictability Is the Deeper Issue
Whitaker said AdvaMed wants a zero-tariff model or, failing that, a low-tariff model. He also emphasized consistency, arguing that repeated shifts in tariff levels make it difficult for companies to run global businesses with confidence.
“The back and forth of it — is it 10%, is it 5%, is it 25% — is not helpful to anybody who runs a global business because you need predictability, hard predictability,” he said.
The business logic is straightforward. Medical device manufacturing often relies on international sourcing for components, assembly, or finished goods, and tariff volatility can raise input costs before revenue has even materialized. In a sector where margins can be shaped by regulatory delays, supply disruptions, and hospital purchasing cycles, even modest tariff changes can ripple through product strategy. A company facing uncertain duties may hesitate to expand production, delay launches, or pass higher costs on to providers already under reimbursement pressure.
The broader clinical consequence emerges later in the chain. When manufacturers absorb cost shocks, those pressures can influence which technologies are scaled, which hospitals can afford to adopt them, and how quickly newer diagnostics or implants spread into routine care. Price stability is not a policy abstraction for medtech; it can determine whether a device reaches patients at all.
FDA User Fees Remain a Cornerstone of the Regulatory Pipeline
AdvaMed also wants renewal of the FDA’s medical device user-fee program, a mechanism that has long linked industry payments to agency review capacity. Under MDUFA, manufacturers pay fees when they submit a premarket application or register their facilities, and those funds help support the FDA’s review infrastructure. The next agreement, MDUFA VI, would cover fiscal years 2028 through 2032 and is awaiting congressional action.
Whitaker framed the issue as one of preserving process quality rather than reinventing the system.
“I think the biggest issue is just maintaining the quality of the process that exists right now, and making sure that continues,” he said.
That emphasis matters because the medtech sector depends on a regulatory pathway that can handle everything from low-risk tools to sophisticated implanted systems and software-driven diagnostics. When review timelines become uncertain, companies face higher carrying costs and a slower route to market. Hospitals and clinicians, in turn, wait longer for devices that may improve diagnosis, procedural safety, or monitoring.
The stakes are especially high as technology cycles shorten. Digital health tools, connected monitors, and software-enabled devices evolve faster than traditional capital equipment, but they still require regulatory confidence before they can be widely deployed. A stable user-fee framework helps sustain the FDA capacity needed to evaluate those products without sacrificing rigor.
Coverage Clarity Could Decide Whether Devices Reach Routine Practice
Whitaker also pushed for greater transparency in payment and coverage policy. He argued that the FDA offers more predictability than the payer side and said manufacturers need clearer signals about what federal payers require for coverage decisions.
“Coverage is important,” he said. “A payment is important, but probably even more important than that is to understand what federal payers need in order to get your product covered today. … If we can get a global market that is steady and predictable, we have an FDA that’s steady and predictable, and then a payment environment that allows us to understand how to navigate payment and coverage, this is an industry that’s going to just take off.”
Reimbursement uncertainty can block adoption even after a device clears regulatory review. A hospital may be willing to evaluate a product clinically but still hesitate if the payment pathway is unclear or if coverage criteria are opaque. For manufacturers, that gap can be especially painful in categories where real-world uptake depends on payer alignment, not just physician enthusiasm.
The point reaches beyond business strategy. In medicine, a technology that cannot secure coverage often remains confined to early adopters or affluent systems, leaving broader patient access uneven. Transparent rules would not guarantee universal adoption, but they would give companies and providers a more workable map for navigating coverage decisions and budgeting for new care pathways.
Connected Care Makes Cybersecurity a Clinical Infrastructure Problem
Whitaker’s final priority was data access and cybersecurity, which he placed alongside connected care as the healthcare system becomes more networked. He included “data access, cybersecurity, and all that goes around connected care” among AdvaMed’s top concerns.
The rise of connected devices has changed the risk profile of modern care. A monitor, implant, imaging system, or digital platform no longer functions as a standalone product; it lives inside a broader data ecosystem that can touch clinicians, patients, hospitals, and vendors. When that ecosystem is vulnerable, the consequences can include operational disruption, delayed treatment, and exposure of sensitive health information.
Cybersecurity is no longer an isolated compliance issue. It is part of device reliability, clinical continuity, and patient trust. As healthcare systems integrate more software into bedside care, manufacturers are being pushed to think about security at the same level as performance and usability.
The MedTech Conference remarks point to an industry trying to manage four intertwined pressures at once: import costs, regulatory throughput, reimbursement clarity, and digital security. Each one affects whether a product can be developed, cleared, paid for, and safely used in real-world care. The unresolved question now is how quickly Congress, the FDA, and payers can align around policies that reduce friction without weakening oversight.